Join our community of smart investors

Venture Life’s recovery potential revealed

A manufacturer and distributor of self-care healthcare products endured a perfect storm in 2021, but looks to have turned the corner.
Venture Life’s recovery potential revealed
  • New Chinese distribution partner for two of the group’s leading oral care brands – Dentyl and UltraDEX
  • Directors purchased 300,000 shares at the end of 2021
  • BBI Healthcare and Helsinn starting to make progress on exploring and exploiting the expected synergies

Aim-traded Venture Life (VLG:40p), a developer, manufacturer and distributor of products for the self-care markets, has appointed a new Chinese partner for two of the group’s leading oral care brands – Dentyl and UltraDEX – both of which have established recognition and sales in the China market.

Venture’s previous Chinese partner failed to deliver on its minimum contractual sales targets, so the appointment of UK-based Samarkand is a smart move. The publicly listed group has proven expertise in connecting UK brands to the Chinese consumer, representing large brands such as Omorovicza, Temple Spa and Philip Kingsley.

To continue reading...
Join our Community of Smart Investors
  • Independent full-length company analysis
  • Actionable investment ideas and recommendations
  • Expert investment tools and data
  • Stock screens from Algy Hall
Have an account? Sign in